12 Best Performing Small Cap Stocks So Far in 2025

Page 9 of 11

3. Grail Inc. (NASDAQ:GRAL)

Number of Hedge Fund Holders: 25

Year-to-Date Performance as of February 17: 208.24%

Grail Inc. (NASDAQ:GRAL) is a biotechnology company that develops early cancer detection technologies. Its products include Galleri, a screening test for asymptomatic individuals, and DAC, a diagnostic aid. It is also developing minimal residual disease and other post-diagnostic tests.

Galleri’s revenue reached $25.4 million in Q3 2024, marking a 52% year-over-year increase, with over 250,000 tests sold since the launch. Clinical studies show promising results, which indicate Galleri’s ability to detect aggressive cancers early. Grail Inc. (NASDAQ:GRAL) is actively pursuing FDA approval for Galleri. It’s conducting large-scale studies with 175,000 participants and aiming for Premarket Approval (PMA) submission in H1 2026, with potential FDA approval in H1 2027. It’s also developing a new, automated version of Galleri to increase efficiency. The total Q3 2024 revenue was $28.7 million, up 38% year-over-year. The company has $853.6 million in cash, ensuring a smooth runway into 2028.

Its stock has surged in 2025 due to several factors. Grail Inc. (NASDAQ:GRAL) preannounced 2024 revenue of $124-126 million, exceeding expectations, and reported 137,000 tests sold, up from 94,000 in 2023. Larry Ellison’s comments on using blood tests for cancer vaccines and a partnership with Quest Diagnostics, which enables access to over 500,000 providers, have also boosted investor confidence.

Page 9 of 11